Clinical Trials

Sanofi announces long-term efficacy data for Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at the 28th Annual Congress of the World Muscle Society (WMS) in Charleston, South Carolina, US.
The data shared included results from the phase 3 COMET trial evaluating the long-term efficacy, safety and durability of the drug in patients with late-onset Pompe disease, with the nearly three-year data showing that patients on the drug had improvement or stabilisation of respiratory function and mobility. The data also showed that the drug was well tolerated by patients who had previously been treated with alglucosidase alfa.
Alaa Hamed MD MPH MBA, global head of medical affairs for Rare Diseases at Sanofi, commented: “Our findings being shared at WMS build upon existing evidence that supports the value of Nexviazyme in treating Pompe disease. With efficacy and safety demonstrated across a variety of patient cohorts, we remain confident in Nexviazyme as a compelling treatment option.”
Nexviazyme is approved in the US and elsewhere as a monotherqapy for the treatment of late-onset Pompe disease, and is approved for infantile-onset Pompe disease in Europe and other countries. The drug is currently in a phase 3 trial for infantile-onset Pompe disease in the US.